Latest news with #Cardiovascular
Yahoo
4 days ago
- Business
- Yahoo
Oppenheimer Lifts Boston Scientific (BSX) PT to $118 Following Strong Q2 Results
Boston Scientific Corporation (NYSE:BSX) is one of the most profitable growth stocks to buy according to billionaires. On July 24, Oppenheimer raised its price target for Boston Scientific from $110 to $118, while maintaining a Perform rating on the shares. The adjustment followed the release of the company's Q2 2025 financial results. In Q2, Boston Scientific generated a revenue of ~$5.1 billion, which was a 22.8% increase year-over-year. Adjusted EPS for the quarter was $0.75, compared to $0.62 in Q2 2024. The company's Cardiovascular division saw the strongest growth with a 26.8% increase in net sales, while the MedSurg segment grew by 15.7%. An engineer observing the inner workings of a medical device during its prototyping phase. Boston Scientific also received US FDA approval for its FARAPULSE Pulsed Field Ablation/PF System to treat symptomatic persistent atrial fibrillation. It also commenced enrollment in the ReMATCH IDE clinical trial for its FARAWAVE and FARAPOINT PFA Catheters. Internationally, the company received CE mark approval for its WATCHMAN FLX Pro Left Atrial Appendage Closure Device. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties. It has two segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Mint
31-07-2025
- Health
- Mint
Heart age calculator: Check your ‘heart age' — it can even predict disease risk and more
A recent study has suggested that the heart's age for several Americans could be a decade older than their actual age. In the United States, heart disease serves as the leading cause of death, and the research highlights that the heart might be aging faster compared to the rest of the body, Today reported. Dr Sadiya Khan, the Magerstadt professor of cardiovascular epidemiology at Northwestern University Feinberg School of Medicine, told the news outlet that doctors usually give a percentage to talk about the patient's risk for a heart-related disease. Khan, along with her team, conducted a study to get a less abstract and more relatable way through which the risk of heart disease can be conveyed. For this, they worked around the idea of 'heart age,' since she said it is "a lot easier to understand". As part of their study, the researchers designed a heart age calculator that was based on the criteria set by the American Heart Association. Their work was published in the JAMA Cardiology earlier this week. The Predicting Risk of Cardiovascular Disease Events (PREVENT) tool of the American Heart Association tells people about their estimated risk for cardiovascular disease by taking into consideration various information, such as blood pressure, BMI, cholesterol levels, medications, and others. Taking a step forward, the new study has translated the risk percentages it provides into heart risk "ages," Today reported. Further, they tested this tool by utilizing data from a nationally representative sample of over 14,000 people, who were in the 30 to 79 age group. Notably, none of them had any history of cardiovascular disease. Sadiya Khan and her team used this data to calculate the heart age of these people and then compared it to their actual chronological ages. They found out that for many samples, the heart's risk age stood greater than the chronological age. The study mentions that men's heart risk age was found to be seven years older than their chronological age on average. On the other hand, the age gap for women was four years. Khan said it was "not that meaningful" if the age gap is off by one or two years, but she recommends people stay concerned if this gap is five years or more. Also, the study highlights that the heart age of Black men in the US was 8.5 years older than their chronological age, while it was found to be 6.2 years for white men. Meanwhile, Black women's hearts were 6.2 years older compared to their actual age, and the gap for white women was found to be 3.7 years. Usually, this is when the heart age remains equal to the person's chronological age. There are specific tools available online to calculate your heart age. Yes, it is possible. Experts suggest that people bring in healthy lifestyle changes to improve heart age.
Yahoo
29-06-2025
- Business
- Yahoo
Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs
SNS Insider Unveils Strategic Insights into the U.S. Cardiovascular Information System Market's Acceleration—Valued at USD 0.33 Billion in 2023—With North America Leading the Market at Over 37% Share in the Face of Rising Demand for Cardiac Data Integration and Workflow Efficiency. Austin, June 29, 2025 (GLOBE NEWSWIRE) -- Cardiovascular Information System Market Size & Growth Analysis: According to SNS Insider, the Cardiovascular Information System Market was valued at USD 1.24 billion in 2023 and is projected to reach USD 2.8 billion by 2032, growing at a CAGR of 9.4% over the forecast period of 2024–2032. The increasing prevalence of cardiovascular diseases and the need for extensive data management in cardiac care are driving the growth of the global cardiovascular information system market. Emerging technologies including cloud-based solutions, artificial intelligence, and EHR interoperability, are filling clinical workflows. Furthermore, increasing digitization of healthcare, in addition to an improved patient outcomes plan, is anticipated to propel widespread adoption of CVIS across hospitals & specialty care a Sample Report of Cardiovascular Information System Market@ The U.S. cardiovascular information system market was estimated at USD 0.33 billion in 2023 and is expected to reach USD 0.73 billion by 2032, at a CAGR of 8.64% during the forecast period of 2024-2032 The North American cardiovascular information system market is dominated by the U.S., attributable to high-end healthcare infrastructure combined with high acceptance of electronic health records and huge investments in digital health technologies. The major CVIS vendors based in this country, coupled with the large number of cardiovascular procedures performed, are continuing to drive the U.S. to a commanding lead in the region. Major Players Analysis Listed in this Report are: Philips Healthcare (IntelliSpace Cardiovascular, Xcelera) Siemens Healthineers (syngo Dynamics, GE Healthcare (Centricity Cardio Enterprise, MUSE Cardiology Information System) McKesson Corporation (McKesson Cardiology, Horizon Cardiology) Agfa Healthcare (IMPAX CV, Enterprise Imaging for Cardiology) Fujifilm Medical Systems (Synapse Cardiovascular, Synapse VNA) LUMEDX Corporation (CardioStar, HealthView CVIS) Cerner Corporation (PowerChart Cardiovascular, CVNet) Merge Healthcare (an IBM Company) (Merge Cardio, Merge Hemo) Digisonics Inc. (DigiView, DigiNet Pro) Cardiovascular Information System Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.24 Billion Market Size by 2032 US$ 2.8 Billion CAGR CAGR of 9.4% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis: Based on the System, the CVIS Segment Leads the Market In 2023, the cardiovascular information system (CVIS) segment held the highest market share due to the fact that it supports the management, storage, and analysis of cardiovascular data from multiple modalities. By enabling image archiving, real-time access, and clinical EHR integration, CVIS boosts workflow efficiency in cardiac care. Use has also grown, due to the growing need for centralized data management and interoperability within healthcare settings. Web-Based Segment Dominates the Market by Mode of Operation The web-based segment accounted for the largest share in 2023 with a 73% market share, owing to the ease with which this type of system can be deployed, its scalability, and cost-effectiveness. These are essential systems for timely decision-making in cardiovascular care, and their connectivity helps provide real-time access to patient data from various locations. Because they demand little to no infrastructure and integrate easily with existing hospital networks, healthcare providers are increasingly opting for a web-based system. By End User, the Hospitals Segment dominated the Cardiovascular Information System Market The hospital segment accounted for the highest share of the CVIS market in 2023. Due to the high number of cardiovascular procedures carried out in a hospital setting, as well as the healthcare organizations' demand for integrated data management systems. SCV and other partners' healthcare professionals, complex imaging workflows, imaging data, and patient records that hospitals manage require comprehensive solutions such as CVIS. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Cardiovascular Information System Market Segmentation By Mode Of Operation Web-based Cloud-based On-site By System CVIS CPACS By End User Hospitals Large Hospitals Medium-sized Hospitals Small Hospitals Diagnostic Centers Regional Trends: North America to Dominate Cardiovascular Information System Market; Asia-Pacific to Witness Fastest Growth The cardiovascular information system (CVIS) market was dominated by North America in 2023, with 37% market share, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of health IT systems in this region. From the perspective of the growth factors, major industry presence, solid government support & initiatives for EHR, and large investment in hospitals' digitization were a few that complemented the market growth. The Asia-Pacific region is anticipated to exhibit the fastest growth over the forecast period in the cardiovascular information system market. Some of the major factors driving the growth of the cardiovascular diagnostics market are rapid urbanization, increasing healthcare spending, and increasing awareness of the importance of good cardiovascular health. Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Adoption Rates of CVIS, 2023 5.2 Device Integration Trends, 2023 5.3 Healthcare Spending on CVIS, by Region, 2023 5.4 Regulatory Compliance and Standardization Trends 5.5 Feature Adoption Trends, 2023 6. Competitive Landscape 7. Cardiovascular Information System Market by Mode Of Operation 8. Cardiovascular Information System Market by System 9. Cardiovascular Information System Market by End User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Buy a Single-User PDF of Cardiovascular Information System Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
16-05-2025
- Health
- Zawya
Merck Foundation Marks ‘World Hypertension Day' 2025 – Transforming Hypertension, Cardiovascular and Diabetes Care in Africa and Beyond by Providing 863 Scholarships for Doctors From 52 Countries
Merck Foundation ( the philanthropic arm of Merck KGaA Germany, marks 'World Hypertension Day 2025' in partnership with Africa's First Ladies, Ministries of Health, Medical Societies and Academia through their 'Nationwide Diabetes&Hypertension Blue Points Program', by reinforcing its commitment to improving cardiovascular and diabetes care across Africa, and beyond. Senator, Dr. Rasha Kelej, CEO of Merck Foundation stated, 'At Merck Foundation we observe 'World Hypertension Day' by expanding access to quality and equitable care in Hypertension, Diabetes, Endocrinology and Cardiovascular preventive care, which are all co-related, by providing scholarships for young doctors from across Africa and beyond. Together with our Ambassadors, The First Ladies of Africa, and partners like Ministries of Health, Medical Societies and Academia, we have till today provided more than 860 scholarships for young doctors from 52 countries, of One-Year Online PG Diplomas and Two-Year Online Master's Degrees in Diabetes, Preventative Cardiovascular Medicine, Endocrinology, Cardiology, and Obesity&Weight Management, as well as One-Year Clinical Cardiovascular Care and Clinical Diabetes Onsite Fellowship Programs in India, a special 3-month Diabetes Mastercourse in English, French, Portuguese, and Spanish languages. What is special about these scholarships is that they have been provided not only to doctors from capital cities, but also to those from across the country — ensuring wider geographic coverage of healthcare capacity. We remain committed to continuing our efforts to improve healthcare capacity and access to hypertension and diabetes care.' Merck Foundation has in total provided more than 2270 scholarships for doctors from 52 countries in 44 critical and underserved medical specialties. Dr. Dzifa Ahadzi, Merck Foundation alumnus from Ghana shares, 'I have completed my Postgraduate Diploma in Cardiology and currently pursuing MSc in Cardiology. Being a practicing cardiologist, this program has provided me with the opportunity to consolidate my knowledge and apply current advances in cardiovascular care to my clinical practice. Since completing the PG Diploma in Cardiology, I have been involved in establishing a Heart Failure clinic in my hospital that caters to the needs of a diverse population of Heart Failure patients including women with Postpartum cardiomyopathy and Cardio-oncology patients. I am extremely grateful to Merck Foundation for the support and exposure it has provided me. It has inspired me and helped me to improve cardiovascular care amongst the population that I serve.' Merck Foundation scholarships are of great value, given that as per WHO data, the African region has the highest prevalence of hypertension, with approximately 27% of adults affected. Therefore, Merck Foundation has launched several community awareness programs to emphasize on the importance of a healthy lifestyle and raise awareness about diabetes and hypertension prevention, early detection and management. Merck Foundation, together with The First Ladies of Africa, has launched a storybook and its adapted animation Film 'Mark's Pressure'. 'I believe early education is key to building a healthier community. Through our storybook and animation film 'Mark's Pressure', we aim to instill healthy habits in children and youth — like reducing salt and sugar, eating well, exercising, and avoiding smoking. I believe that this is the only way to prevent and manage hypertension and diabetes, which are major risk factors for many serious complications and illnesses.' Watch the 'Mark's Pressure' Animation Film here: Moreover, Merck Foundation's pan African TV program 'Our Africa' conceptualized, produced, directed, and co-hosted by Senator, Dr. Rasha Kelej, CEO of Merck Foundation has episodes dedicated to raising awareness about Diabetes and Promoting Healthy Lifestyle. Watch the Episodes here: 'Our Africa' TV Program has been broadcasted on National and Prime TV stations of many African countries like Burundi, Botswana, Ghana, The Gambia, Kenya, Liberia, Malawi, Mauritius, Namibia, Sierra Leone, Uganda, Zambia and is currently on social media handles of Senator, Dr. Rasha Kelej (Facebook ( Instagram ( Twitter ( and YouTube ( and Merck Foundation (Facebook ( Instagram ( Twitter ( and YouTube ( Additionally, Merck Foundation together with African First Ladies, also launches annually, their Awards for best Media, Fashion Designers, Filmmakers, Musicians/ Singers, and new potential talents in these fields from African countries to Promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension. 1. Merck Foundation Media Recognition Awards 2025 'Diabetes&Hypertension': Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2025. 2. Merck Foundation Film Awards 2025 'Diabetes&Hypertension': All African Filmmakers, Students of Film Making Training Institutions, or Young Talents of Africa are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle raise awareness about prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2025. 3. Merck Foundation Fashion Awards 2025 'Diabetes&Hypertension': All African Fashion Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2025. 4. Merck Foundation Song Awards 2025 'Diabetes&Hypertension': All African Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2025. Distributed by APO Group on behalf of Merck Foundation. Additional Images: Contact details: Mehak Handa Community Awareness Program Manager +91 9310087613 / +91 9319606669 Join the conversation on our social media platforms below and let your voice be heard! Facebook: X: YouTube: Instagram: Threads: Flickr: Website: About Merck Foundation: The Merck Foundation, established in 2017, is the philanthropic arm of Merck KGaA Germany, aims to improve the health and wellbeing of people and advance their lives through science and technology. Our efforts are primarily focused on improving access to quality&equitable healthcare solutions in underserved communities, building healthcare&scientific research capacity, empowering girls in education and empowering people in STEM (Science, Technology, Engineering, and Mathematics) with a special focus on women and youth. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website. Please visit to read more. Follow the social media of Merck Foundation: Facebook ( X ( Instagram ( YouTube ( Threads ( and Flickr ( The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors.
Euronews
06-02-2025
- Business
- Euronews
AstraZeneca reports strong results boosted by promising trials
Pharmaceutical giant AstraZeneca announced its fourth quarter and full year 2024 earnings on Thursday. Product sales for the fourth quarter came up to $13.4 billion (€12.9bn), which was a rise of 18% in actual terms. Total revenue for Q4 2024 was $14.9bn (€14.4bn), which was a surge of 24%. Core earnings per share (EPS) came up to $2.09 (€2.0), which was a jump of 44%. For the full year 2024, product sales came up to $50.9bn (€49.1bn), an increase of 16%, whereas total revenue grew 18% to $54.1bn (€52.2bn). Core EPS advanced 13% to $8.21 (€7.9). These robust figures were mainly driven by a number of promising trials, with the company delivering nine positive high value Phase III studies during the full year 2024. AstraZeneca has seen rising demand for its drugs across all of its main markets in 2024 as well. This is expected to go a long way in helping the company grow this year. Pascal Soriot, the chief executive officer (CEO) of AstraZeneca, said in the fourth quarter and full year earnings report on the company's website: 'This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80bn total revenue by the end of the decade. 'In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines. We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth well beyond 2030, many of which have now entered pivotal trials.' Strong trials and pipeline continue to support AstraZeneca growth AstraZeneca's main departments saw increasing growth in 2024, with total revenue from Oncology rising 24%. Rare Disease total revenue grew 16%, whereas Cardiovascular, Renal and Metabolism (CVRM) total revenue jumped 20%. Respiratory and immunology total revenue also surged 25%, with vaccines and immune therapies (V&I) total revenue advancing 8% as well. Russ Mould, investment director at AJ Bell, said in an email note: 'AstraZeneca is in rude health. It has delivered a solid set of numbers, beating market expectations on both the revenue and earnings lines. 'A good run of Phase III trials during the year bodes well for converting the pipeline of drug developments into the next generation of products to sustain earnings growth. Having something else ready on the conveyer belt is paramount to the success of pharma companies as they face patent cliffs. 'China import-related tax issues won't derail the business. They're just noise and any fines will be small fry relative to the typical outflows from a company the size of AstraZeneca. Unlike GSK which delivered a lopsided performance thanks to weakness in its vaccines arm, AstraZeneca looks more balanced with gains recorded across all therapy areas. 'So far, so good, yet AstraZeneca needs to sustain this strong momentum if it is to achieve ambitious medium-term goals.'
